The NOTCH gene was identified approximately 110 years ago. Classical studies have
revealed that NOTCH signaling is an evolutionarily conserved pathway. NOTCH receptors …

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

PURPOSE Small-cell lung cancer (SCLC) is an aggressive malignancy with limited
treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab …

Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Dysregulation of the Notch signaling pathway, which is highly conserved across species,
can drive aberrant epigenetic modification, transcription, and translation. Defective gene …

Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises
de novo only rarely; the disease predominantly develops from adenocarcinoma in response …

Programmed death-ligand 1 [PD-(L) 1], cytotoxic T-lymphocyte associated protein 4 (CTLA-
4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor
prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately …